71 results on '"Granberg, Dan"'
Search Results
2. 630 EO2401, a new peptide immunotherapy against cancer, in combination with nivolumab, induces a strong and durable immune response in patients from the EOADR1–19/SPENCER study
3. Improved health‐related quality of life during peptide receptor radionuclide therapy in patients with neuroendocrine tumours
4. EO2401, a novel microbiome-derived therapeutic vaccine for patients with adrenocortical carcinoma (ACC): Preliminary results of the SPENCER study.
5. A Phase II Trial of a Personalized, Dose-Intense Administration Schedule of 177Lutetium-DOTATATE in Children With Primary Refractory or Relapsed High-Risk Neuroblastoma–LuDO-N
6. Neuroendocrine Tumors of the Lung
7. Biochemical Testing in Patients with Neuroendocrine Tumors
8. Metastatic Pheochromocytomas and Abdominal Paragangliomas
9. A Randomized Cross-Over Study in Patients with Neuroendocrine Tumors (NETs) To Assess Patient Preference for Lanreotide Autogel Given by Self/Partner or Given by Healthcare Professional
10. 177Lu-DOTATATE Therapy of Advanced Pancreatic Neuroendocrine Tumors Heavily Pretreated with Chemotherapy: Analysis of Outcome, Safety, and Their Determinants
11. Neuroendocrine tumours
12. Favorable Outcome in Patients with Pheochromocytoma and Paraganglioma Treated with 177Lu-DOTATATE
13. Bronchial carcinoids
14. Peptide receptor radionuclide therapy in gastroenteropancreatic NEN G3: a multicenter cohort study
15. Prospective observational study of 177Lu-DOTA-octreotate therapy in 200 patients with advanced metastasized neuroendocrine tumours (NETs): feasibility and impact of a dosimetry-guided study protocol on outcome and toxicity
16. Kidney dosimetry during 177Lu-DOTATATE therapy in patients with neuroendocrine tumors: aspects on calculation and tolerance
17. Serotonin, ATRX, and DAXX Expression in Pituitary Adenomas
18. Serotonin, ATRX and DAXX as differential diagnostic markers of neuroendocrine tumours (NETs) in the sellar region. An immunohistochemical study in a large series of pituitary adenomas and in a non-pituitary NET
19. Neuroendocrine tumors with syndromic vasoactive intestinal polypeptide hypersecretion: a retrospective study
20. Patient-Reported Burden of a Neuroendocrine Tumor (NET) Diagnosis: Results From the First Global Survey of Patients With NETs
21. Whole-body MRI including diffusion-weighted MRI compared with 5-HTP PET/CT in the detection of neuroendocrine tumors
22. Selective internal radiation therapy in patients with progressive neuroendocrine liver metastases
23. Streptozocin and 5-Fluorouracil for the Treatment of Pancreatic Neuroendocrine Tumors: Efficacy, Prognostic Factors and Toxicity
24. Lung neuroendocrine tumor (NET) patient (pt)-reported experience: Results from the first global NET pt surveyA collaboration between the international neuroendocrine cancer alliance (INCA) and Novartis pharmaceuticals.
25. Dose Response of Pancreatic Neuroendocrine Tumors Treated with Peptide Receptor Radionuclide Therapy Using 177Lu-DOTATATE
26. Lung and Thymic Neuroendocrine Tumors
27. Bronchial carcinoids
28. Integrative Genetic Characterization and Phenotype Correlations in Pheochromocytoma and Paraganglioma Tumours
29. Quantitative and Qualitative Intrapatient Comparison of 68Ga-DOTATOC and 68Ga-DOTATATE: Net Uptake Rate for Accurate Quantification
30. Comparative Biodistribution and Radiation Dosimetry of 68Ga-DOTATOC and 68Ga-DOTATATE in Patients with Neuroendocrine Tumors
31. Somatic Mutations in H-RAS in Sporadic Pheochromocytoma and Paraganglioma Identified by Exome Sequencing
32. MAX mutations status in Swedish patients with pheochromocytoma and paraganglioma tumours
33. Next-generation sequencing in the clinical genetic screening of patients with pheochromocytoma and paraganglioma
34. Metastases from Neuroendocrine Tumors to the Breast Are More Common than Previously Thought. A Diagnostic Pitfall?
35. Everolimus Plus Octreotide Long-Acting Repeatable in Patients With Advanced Lung Neuroendocrine Tumors
36. Biotherapy: somatostatin analogs and IFN-α
37. Treatment, prognostic markers and survival in thymic neuroendocrine tumours. A study from a single tertiary referral centre
38. Effect of Temozolomide in Patients with Metastatic Bronchial Carcinoids
39. Individualized Dosimetry of Kidney and Bone Marrow in Patients Undergoing 177Lu-DOTA-Octreotate Treatment
40. Randomized crossover study in patients with neuroendocrine tumors to assess patient preference for lanreotide Autogel® given by either self/partner or a health care professional
41. The Cytotoxic Effect of Emetine and CGP-74514A Studied with the Hollow Fiber Model and ArrayScan Assay in Neuroendocrine Tumors In Vitro
42. Treatment of Liver Metastases in Patients with Neuroendocrine Tumors
43. Lessons on Tumour Response: Imaging during Therapy with 177Lu-DOTA-octreotate. A Case Report on a Patient with a Large Volume of Poorly Differentiated Neuroendocrine Carcinoma
44. Minor changes in effective half-life during fractionated177Lu-Octreotate therapy
45. Appendiceal Adenocarcinoids with Peritoneal Carcinomatosis Treated with Cytoreductive Surgery and Intraperitoneal Chemotherapy: A Retrospective Study of In Vitro Drug Sensitivity and Survival
46. Faculty Opinions recommendation of Sunitinib malate for the treatment of pancreatic neuroendocrine tumors.
47. Response to temozolomide and bevacizumab in a patient with poorly differentiated neuroendocrine carcinoma
48. Faculty Opinions recommendation of Pancreatic cystic endocrine tumors: a different morphological entity associated with a less aggressive behavior.
49. Five patients with malignant endocrine tumors treated with imatinib mesylate (Glivec®)
50. Individualized dosimetry in patients undergoing therapy with 177Lu-DOTA-D-Phe1-Tyr3-octreotate
Catalog
Books, media, physical & digital resources
Discovery Service for Jio Institute Digital Library
For full access to our library's resources, please sign in.